logo

For the Inventor, By the Inventor

Berlin, Germany

Glycotope Gmbh


USPTO Granted Patents = 26

% Expired Patents = 42.3



Trademarks = 2

Forward Citations = 93

Loading Chart...
Loading Chart...

28 inventors (with patents filed for the assignee):

goldMedal Steffen Goletz (22 out of 25 patents)

silverMedal Antje Danielczyk (10 out of 16 patents)

bronzeMedal Renate Stahn (6 out of 8 patents)

4.  Uwe Karsten (6 out of 9 patents)

5.  Lars Stöckl (5 out of 6 patents)

6.  Hans Baumeister (5 out of 6 patents)

7.  Philippe Ulsemer (3 out of 3 patents)

8.  Anja Löffler (3 out of 3 patents)

9.  Frederick Gyapon Quast (2 out of 3 patents)

10.  Jan Susan Rosenbaum (2 out of 12 patents)

11.  Matthias Kaup (2 out of 3 patents)

12.  Lars Stoeckl (2 out of 2 patents)

13.  Rik J Scheper (2 out of 2 patents)

14.  Alan Masterson (2 out of 2 patents)

15.  Herbert M Pinedo (2 out of 2 patents)


Core Competencies:
Surfactant Protein D
Anti-MUC1 Antibody
Eukaryotic Expression Vectors
Tumor Antigens
Immunostimulating Mucins
Humanized EGFR Antibodies
MUTZ-3 Dendritic Cells
Glycoprotein Purification
Cellular Immunity
Tumor Detection
Microorganisms
Tumor Cell Lines

26 patents:

1. 12391956 - Methods, compositions and cells for preparing surfactant protein D (SP-D) (2025-08-19),
2. 12297289 - Anti-MUC1 antibody (2025-05-13),
3. 10752914 - Methods, compositions and cells for preparing surfactant protein D (SP-D) (2020-08-25),
4. 10280230 - Use of human cells of myeloid leukemia origin for expression of antibodies (2019-05-07),
5. 10184135 - Eukaryotic expression vectors comprising regulatory elements of the globin gene clusters (2019-01-22),
6. 9845361 - Recognition molecules for the treatment and detection of tumors (2017-12-19),
7. 9700610 - Microorganisms carrying a tumor antigen (2017-07-11),
8. 9527899 - Recombinant human follicle-stimulating hormone (2016-12-27),
9. 9494587 - Microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates (2016-11-15),
10. 9487567 - Method for the production of an immunostimulating mucin (MUC1) (2016-11-08),
11. 9359439 - Fab-glycosylated antibodies (2016-06-07),
12. 9359427 - Methods for culturing human myeloid leukaemia cells and cells derived therefrom (2016-06-07),
13. 9217038 - MUC1 antibodies (2015-12-22),
14. 9051370 - Humanized EGFR antibodies (2015-06-09),
15. 9051356 - Use of human cells of myeloid leukaemia origin for expression of antibodies (2015-06-09),
Glycotope GmbH, based in Berlin, specializes in the development and manufacturing of glyco-engineered biopharmaceuticals. The company focuses on advancing therapeutic proteins and monoclonal antibodies through innovative glycosylation techniques, enhancing their efficacy and safety profiles. Glycotope's expertise spans various domains, including oncology and immunotherapy, positioning it as a key player in the biopharmaceutical landscape. The organization is committed to leveraging cutting-edge technology to address unmet medical needs globally.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Glycotope Gmbh
26 Patents

#39 in D-1000 Berlin

#1,785 in Germany

#24,781 in the World

Berlin, DE
Berlin, Germany

Glycotope Gmbh

Forward Citations = 93

28 inventors:

goldMedal Steffen Goletz (22 out of 25 patents)

silverMedal Antje Danielczyk (10 out of 16 patents)

bronzeMedal Renate Stahn (6 out of 8 patents)

4.  Uwe Karsten (6 out of 9 patents)

5.  Lars Stöckl (5 out of 6 patents)

Please report any incorrect information to [email protected]
Loading…